Close Menu

intellectual property

New York University has been awarded

Gen-Probe (Hologic) has also been awarded

NEW YORK (GenomeWeb) – The US District Court for the Middle District of North Carolina has denied a motion brought by GlaxoSmithKline that sought to dismiss a patent infringement suit Genetic Technologies had filed against the drug giant two year ago.

Lawrence Livermore National Security has been awarded

NEW YORK (GenomeWeb News) — Roche Molecular Systems has sued Cepheid for allegedly infringing a US patent assigned to Roche and covering PCR-based methods for detecting Mycobacterium tuberculosis and drug resistance, according to court documents filed this week.

Title: Oligoribonucleotides and Methods of Use Thereof for Treatment of Alopecia, Acute Renal Failure, and Other Diseases
Patent Number: 8,765,699

The USPTO recently issued the Broad Institute the first patent for the CRISPR-Cas9 system, setting off a potential scramble for IP rights over a technology that is gaining wide adoption in the biotech space.

COLD SPRING HARBOR, NY (GenomeWeb) – At an ethical, legal, and social implications (ELSI) panel at the Biology of Genomes meeting here yesterday afternoon, legal experts discussed the current climate surrounding gene patenting and the key court cases leading up to it.

Title: Methods for Eliminating or Reducing the Expression of a Gene in a Filamentous Fungal Strain
Patent Number: 8,716,023

Title: System for Targeted Delivery of Therapeutic Agents
Patent Number: 8,709,483
Filed: Sept. 26, 2008

Pages

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.